October 26, 2011 - Investorideas.com, a leader in sector research for independent investors issues an investor snapshot for TSX biotech stock, Verisante (TSX-V: VRS) following its October 19 th news, receiving Health Canada's approval for their innovative skin cancer detection device. The stock immediately moved up to over $1.00 on significant volume once the news was disseminated.
Verisante Receives Health Canada Approval for Verisante Aura(TM)!
VANCOUVER, BRITISH COLUMBIA -(10/19/11)- Verisante Technology, Inc. (TSX-V: VRS) (OTCQX: VRSEF.PK)(PINK SHEETS: VRSEF) a leader in cancer imaging technology, announced today that it has obtained a license from Health Canada to market and sell the Verisante Aura™, an innovative, non-invasive medical device for the early detection of skin cancer.
"Obtaining a license from Health Canada means we are now able to begin marketing and selling Verisante Aura™ in Canada. This is a defining milestone for our Company," said President and CEO Thomas Braun. " Our technology has the ability to revolutionize the way skin cancer is diagnosed, saving lives and costs. Verisante Aura™ will aid healthcare professionals in assessing skin lesions, reducing patient wait times and decreasing healthcare costs by detecting skin cancer at an early and most easily treatable stage."
Verisante Technology, Inc Key Facts:
Revolutionary, patent-protected, platform technology!
- Applicable to several forms of cancer
- Clear regulatory pathway that will result in significant early revenue
- Imaging device for the safe detection of skin cancer now approved for sale in Canada
- Strategic alliances with leading institutions
- World class scientific capability
- Project management led by experienced, award-winning pioneers
- Medical and technical team led by renowned experts
- Highly qualified management, and Strong, independent board
- Raised $8.7 million in 2011, ensuring sufficient funding through commercialization
Verisante Technology, Inc. is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Company's device for skin cancer detection, Aura™, is approved for sale in Canada. Approval in Europe and Australia is expected by the end of 2011. Verisante's AuraTM and Core™ (for lung, colon and cervical cancer detection) devices utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. This exclusive platform technology allows Verisante to develop compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers. Visit www.verisante.com
Verisante Technology, Inc.
306 - 2309 West 41st Avenue
Vancouver BC V6M 2A3
Tel 604 605 0507
Fax 604 605 0508
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock
Disclosure: Investorideas.com has been compensated one thousand to advertise Verisante technology and distribute news releases and content on their behalf by a third party IR firm. All information in this report is within the public domain and previously released by the company. All investment involves risk and possible loss of investment.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - www.Investorideas.com